9/107 sources · 3 publishersUpdated Oct 22, 03:32 UTC
Arcus Biosciences launches and prices a $250 million public stock offering
Arcus Biosciences announced an underwritten public offering of common stock and priced the deal on October 22. The company sold roughly 14.3 million shares at $17.50 each, raising $250 million before expenses. Underwriters have a 30‑day option to purchase up to an additional 15% of the shares, and the closing is expected on October 23, 2026, subject to customary conditions.
Why it matters
The company says the proceeds will be used to fund its cancer and immune‑disease programs, expanding its pipeline. The new equity raises capital but also dilutes existing shareholders, which may affect the stock price.
Key facts
- 1Arcus priced the offering at $17.50 per share, raising $250 million. tradingview.com
- 2The offering comprised about 14.3 million shares. tradingview.com
- 3Underwriters have a 30‑day option to buy up to an additional 15% of the shares offered. investing.com
- 4Closing of the offering is expected on October 23, 2026, pending customary conditions. tradingview.com
- 5Jefferies, Leerink Partners, TD Cowen, Evercore ISI and Mizuho are serving as joint book‑running managers. stocktitan.net
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.